about
Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host diseaseScoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome[Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.Evaluation of prognostic factors among patients with chronic graft-versus-host disease.Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy.The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect.A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.Do Patients and Physicians Agree When They Assess Quality of Life?Imported Disease Screening Prior to Chemotherapy and Bone Marrow Transplantation for Oncohematological Malignancies.Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin.Excess mortality in the myelodysplastic syndromes.Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.Post-Thaw Viable CD45+ Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in Adult Patients with Malignant Diseases.Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab.Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.Primary gastrointestinal aspergillosis 6 months after allogeneic hematopoietic cell transplantation: a case report.Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning.Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT.Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission.A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
P50
Q28272414-29A62C3C-DECB-404D-9D5B-E2DE3F9A85B6Q30353404-FCB520D0-0DB5-4748-B98A-3BA76BC9AB1CQ30371042-B6170DB3-FDC7-4DE9-865F-8A28B4122CC2Q33413487-003DEA8A-70E6-4C14-AAF8-0E78F9EF6874Q33419220-5692BA32-C752-43B6-BCC8-3CF4E49DF185Q35082549-2345FD34-5EF0-4C51-94ED-4A8FFD01BAC6Q36133013-7DDD1F5E-E20B-441B-B040-FE7943C37584Q36812193-539A98F0-DE32-4695-AA51-E290FF5C68C2Q36862464-58940A80-D285-47B8-B7B8-FA5FE031ED35Q36956129-8EFA3143-D26F-4E7D-BD3F-175A4043BEB6Q37061969-EC376E69-2E65-4817-8744-505A5B3112E8Q37592994-3D01AC36-757B-4563-B7D0-822E08F13BDBQ38843695-12A794A8-6649-4AB7-83DE-E6234C8ADFF9Q39059436-5BB7CF6B-2D72-42C0-AB73-6F6E481F4E96Q39182177-BEE075A2-96B6-4BBC-998F-DC4623306EC2Q40294400-0CB6E981-1B55-40AA-9FCC-23C2D24CC096Q40419395-E309E9A5-7236-431D-8731-6D2768A5246AQ40435632-885A0BB8-6291-4B58-924E-5D3B9528E302Q40470007-A35B2F24-D82E-4163-A9DF-029194BEEE24Q40486613-9DE3B8D1-B4C0-4EB2-AE64-366298A5797BQ40551837-D74707A5-22E1-4870-A9C5-742CE09F1801Q40974681-9243115E-1C06-4657-BB58-609B0B95BDF0Q41077546-611BCCC3-1411-4415-BA17-3039083BE8C2Q41406968-EB722BDB-1554-4723-858A-9EF1ECE3F04CQ41441272-E881D038-396F-4016-86AF-5F67FB8E2CD6Q41549338-5E8D39BD-9810-4B8D-B4B9-9D188F54B7ADQ41688144-CEA1344A-035B-4943-B35B-7A05B034DB1FQ42267015-D1DC9F79-65EC-4445-B571-20EC185A3759Q43231972-8F07E2B0-B315-43E7-AE7B-417826ED3D59Q43263128-D9CD7546-4B58-44AA-B13A-698C9264FCD2Q43294885-736D03F8-5817-4267-AA8B-7011E66670FBQ43770648-18E13F00-352F-4CF3-AC65-42962B01D4D7Q44093237-8EA272D8-249A-4BF9-B065-1A38DC9EB829Q44360456-4D4A9366-5524-40FE-A184-C3E0C5134630Q44614482-127BEC16-7307-4AB9-B663-3EA16E6332AFQ45385030-1EBFEFB2-F9B1-4985-A70E-93583D3FD32FQ46168126-0DA37049-A8B5-419B-BBF7-17BB896A9CB8Q46845322-46879413-70C5-42A4-BAC4-777791001181Q46914752-BBBAB9BC-9C54-4D39-9700-FEDC5231E43DQ47099325-4E2BCA4B-EC7F-475C-BF52-7D0F90E1D42C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Valcarcel
@ast
David Valcarcel
@en
David Valcarcel
@es
David Valcarcel
@nl
type
label
David Valcarcel
@ast
David Valcarcel
@en
David Valcarcel
@es
David Valcarcel
@nl
prefLabel
David Valcarcel
@ast
David Valcarcel
@en
David Valcarcel
@es
David Valcarcel
@nl
P106
P1153
6507964068
P21
P31
P496
0000-0002-8747-078X